Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma

Br J Haematol. 2007 Jan;136(1):111-3. doi: 10.1111/j.1365-2141.2006.06371.x. Epub 2006 Nov 20.

Abstract

Enteropathy-associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease, with a poor prognosis due to perforation and gastro-intestinal bleeding during treatment, and a high relapse risk. Six patients were treated with two cycles of IVE (ifosphamide, etoposide, epirubicin), followed by two cycles of high-dose methotrexate (3 g/m(2)) with folinic acid rescue and a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Enteral feeding was given throughout treatment. Four patients remain alive in complete remission at 1.83-4.32 years; two have relapsed. Given the historically poor outcome in these patients, this regimen appears very promising in the treatment of EATL.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carmustine / administration & dosage
  • Celiac Disease / complications*
  • Celiac Disease / immunology
  • Celiac Disease / therapy
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Enteral Nutrition
  • Epirubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Ifosfamide / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Lymphoma, T-Cell, Peripheral / complications*
  • Lymphoma, T-Cell, Peripheral / therapy*
  • Male
  • Melphalan / administration & dosage
  • Methotrexate / therapeutic use
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation*
  • Podophyllotoxin / administration & dosage
  • Transplantation Conditioning
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Epirubicin
  • Etoposide
  • Podophyllotoxin
  • Melphalan
  • Carmustine
  • Ifosfamide
  • Methotrexate

Supplementary concepts

  • BEAM protocol
  • IEV protocol